CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis

Oncotarget

Volumn 8, Issue 24, 2017, Pages 39021-39032

  Liu, Ran ^a   Wei, Huiting ^b   Gao, Peng ^c   Yu, Hu ^b   Wang, Ke ^b   Fu, Zheng ^b   Ju, Baohui ^d   Zhao, Meng ^b   Dong, Shangwen ^b   Li, Zhijun ^b   He, Yifeng ^e   Huang, Yuting ^b   Yao, Zhi ^b  

^a TIANJIN UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF THE DISTRICT OF COLUMBIA   (United States)

^d SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CD47; Macrophage; Monoclonal antibody; Ovarian cancer; Phagocytosis

Indexed keywords

CD133 ANTIGEN; CD47 ANTIGEN; SHORT HAIRPIN RNA; ANTINEOPLASTIC AGENT; CD47 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL INFILTRATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNE EVASION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PHAGOCYTOSIS; PROTEIN EXPRESSION; SK OV 3 CELL LINE; SURVIVAL RATE; SURVIVAL TIME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DISEASE EXACERBATION; DRUG EFFECT; DRUG SCREENING; IMMUNOLOGY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; OVARY TUMOR; PATHOLOGY; PROCEDURES; TUMOR CELL LINE; TUMOR ESCAPE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CD47 ANTIGEN; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; MACROPHAGES; MICE; MICE, INBRED BALB C; OVARIAN NEOPLASMS; PHAGOCYTOSIS; TUMOR ESCAPE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85020652163     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16547     Document Type: Article

References (30)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9-29
2. Huang Y, Zhao M, Xu H, Wang K, Fu Z, Jiang Y, Yao Z. RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasis. Oncotarget. 2014; 5:6734-45. doi: 10.18632/oncotarget.2244
3. Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006; 7:925-34
4. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002; 23:549-55
5. Italiani P, Boraschi D. From Monocytes to M1/M2 Macrophages: phenotypical vs. Functional Differentiation. Front Immunol. 2014; 5:514
6. Oldenborg PA, Gresham HD, Lindberg FP. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med. 2001; 193:855-62
7. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. 2000; 288:2051-54
8. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009; 138:271-85
9. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA. 2012; 109:6662-67
10. McCracken MN, Cha AC, Weissman IL. Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals. Clin Cancer Res. 2015; 21:3597-601
11. Mawby WJ, Holmes CH, Anstee DJ, Spring FA, Tanner MJ. Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. Biochem J. 1994; 304:525-30
12. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res. 2007; 13:1472-79
13. Xiao Z, Chung H, Banan B, Manning PT, Ott KC, Lin S, Capoccia BJ, Subramanian V, Hiebsch RR, Upadhya GA, Mohanakumar T, Frazier WA, Lin Y, Chapman WC. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. Cancer Lett. 2015; 360:302-09
14. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009; 27:2875-83
15. Neuzil J, Stantic M, Zobalova R, Chladova J, Wang X, Prochazka L, Dong L, Andera L, Ralph SJ. Tumourinitiating cells vs. cancer 'stem' cells and CD133: what's in the name? Biochem Biophys Res Commun. 2007; 355:855-59
16. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS, Buckanovich RJ. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 2011; 71:3991-4001
17. Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, Li C, Wang LP, Roby KF, Orsulic S, Connolly DC, Zhang Y, Montone K, et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One. 2010; 5:e10277
18. Huang Y, Ma Y, Gao P, Yao Z. Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy. J Thorac Dis. 2017; 9:E168-74
19. Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM, Volkmer AK, Ozkan E, Fernhoff NB, van de Rijn M, Weissman IL, Garcia KC. Engineered SIRPa variants as immunotherapeutic adjuvants to anticancer antibodies. Science. 2013; 341:88-91
20. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6:pl1
21. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009; 138:286-99
22. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010; 142:699-713
23. Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, Chao M, Weissman IL, Majeti R. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential. PLoS One. 2015; 10:e0137345
24. Oldenborg PA, Gresham HD, Chen Y, Izui S, Lindberg FP. Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice. Blood. 2002; 99:3500-04
25. Wahl RL, Barrett J, Geatti O, Liebert M, Wilson BS, Fisher S, Wagner JG. The intraperitoneal delivery of radiolabeled monoclonal antibodies: studies on the regional delivery advantage. Cancer Immunol Immunother. 1988; 26:187-201
26. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005; 65:3025-29
27. Huang Y, Ju B, Tian J, Liu F, Yu H, Xiao H, Liu X, Liu W, Yao Z, Hao Q. Ovarian cancer stem cell-specific gene expression profiling and targeted drug prescreening. Oncol Rep. 2014; 31:1235-48
28. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012; 481:306-13
29. Malik B, Nie D. Cancer stem cells and resistance to chemo and radio therapy. Front Biosci (Elite Ed). 2012; 4:2142-49
30. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008; 68:4311-20